Investment Pitches

Pitch Summary:
eDreams is a leading European online travel agency that has reinvented itself around Prime, a paid subscription launched in 2017 that now drives ~71% of revenue and over 7.2M members. Prime members book more often at lower acquisition cost, shifting the model from transaction-led to recurring, high-margin revenue. FY2025 Cash EBITDA reached ~€180M (+49% YoY) on €718M revenue as operating leverage kicked in; FCF was ~€100M, enabling deleveraging and ~€80M of buybacks (~9% of float). Management guides to €215–220M Cash EBITDA and >€120M FCF in FY2026, with Prime expansion from 10 to more countries within a 44-market footprint. Penetration is still low (~3.7% of EU households), leaving a long runway for subscriber and ARPU growth (incl. Prime Plus). At €8.27, shares trade near ~10–12× forward P/E and mid-single-digit EV/EBITDA, implying >100% upside if execution continues and the market re-rates the subscription economics. The model has proven resilient through recent macro volatility versus traditional OTAs. Management is channeling rising cash generation into buybacks and balance-sheet strengthening, with net debt/EBITDA trending toward ~1.6× and potential net cash by 2027–28. The pitch frames eDreams as a “value + growth” setup: subscription-style predictability at OTA valuations.

BSD Analysis:
Main risks are macro/travel shocks, competitive subscription responses from larger peers (Booking/Expedia), churn as cohorts mature, and EU regulatory noise. The bear case argues Prime’s growth could slow as early adopters saturate and marketing needs to rise to sustain net adds, pressuring margins; airline distribution disputes can also flare. Still, the cash inflection and buybacks provide downside ballast, and the first-mover subscription advantage (scale, data, tech) raises barriers for copycats. If FY2026 guidance is met, the multiple looks too low for a recurring, high-margin model; if growth wobbles, the current valuation already embeds caution.

Pitch Summary:
Tencent is a dominant Chinese digital platform anchored by WeChat/Weixin’s ~1.4B users and leadership in gaming, fintech (WeChat Pay), online ads, and cloud. The pitch argues the market undervalues Tencent’s core operations (ex-investments) at roughly a legacy-tech multiple despite accelerating monetization from WeChat Video Accounts, mini-program commerce, and a recovering ads cycle. AI is framed as a “growth multiplier”: Tencent’s HunYuan model and rising AI capex are already lifting ad CTRs, speeding content creation, improving game development, and enabling higher-value AI cloud services. Management is returning large amounts of capital via buybacks while margins sit near cycle highs; regulatory headwinds have eased versus 2021–22. Base case envisions steady WeChat ARPU growth, mid-single-digit gaming CAGR with global expansion, and improving cloud mix, taking EBIT from ~RMB 208B (2024) to ~RMB 299B in ~3 years. Upside case embeds broader AI deployment, pushing EBIT >RMB 390B and margins >40%, justifying a rerate. Investment stakes (~RMB 851B) offer additional SOTP support alongside optional divestments. Net, the setup is a durable compounder with asymmetric AI optionality and multiple paths to value realization.

BSD Analysis:
Key risks center on execution and policy: WeChat monetization could bump into user-experience limits as ad load rises; Douyin/Kuaishou competition may siphon ad budgets and attention. Gaming remains hit-driven; aging tentpoles, slower approvals, or new rules on monetization/time limits could crimp growth, while geopolitical scrutiny can hinder overseas M&A/publishing. Cloud price wars may cap margins even as AI workloads grow. China macro/regulatory shifts can reprice platform risk or push further stake divestitures that don’t yield cash. That said, low incremental CAC on WeChat, proven live-ops in games, improving ads signal, and material buybacks create downside buffers; AI-driven efficiency and monetization provide upside torque.

Pitch Summary:
SeaStar Medical is a small-cap medtech developing the Selective Cytopheretic Device (SCD) for immune modulation in critically ill patients. Its pediatric product (QUELIMMUNE) is FDA-approved under HDE and being adopted at children’s hospitals, while the adult AKI pivotal trial is 50% enrolled with interim data due late Q3 2025. Valuation is just $19M market cap with $10M cash, low burn, and warrants outstanding. Pediatric TAM is ~$100M with strong survival benefits, while adult TAM is $4.5B. Upside scenarios include 4–5x returns on adult approval, while downside is partially supported by pediatric business and NOLs. Risks include trial failure, capital raises, warrant overhang, and competition. Still, platform potential across AKI, cardiorenal, ESRD, and sepsis is large, with NIH grants and strong safety record. Pitch frames as asymmetric bet with limited downside.

BSD Analysis:
BSD case: ICU is a binary biotech-like play but with downside cushioned by pediatric approval and optionality. Market cap < $20M underprices platform optionality in multi-billion TAM.

Pitch Summary:
We began accumulating shares of GE Aerospace in April of last year, with our current position established at an average cost of approximately $149 per share. Like Boeing, GE stands to benefit from powerful macro trends including reshoring, increased defense spending, and the global rebound in air travel. But unlike Boeing, GE is not a turnaround story. The company has already successfully repositioned itself as a focused aerospace leader. It’s investing heavily in U.S. factories and suppliers to expand production capacity, improve supply chain resilience, and support reshoring initiatives. GE also plays a critical role in defense. On the commercial side, it powers the majority of widebody aircraft in North America and holds a dominant position in the narrow-body segment through its joint venture with Safran Aircraft Engines, CFM International. GE’s high-margin engine MRO business is another bright spot, poised for growth as airlines extend the life of existing aircraft. In effect, GE benefits both from Boeing’s recovery and from broader structural demand in aviation. We also see GE as an innovation leader—applying AI and digital tools to improve predictive maintenance, streamline inspections, and enhance manufacturing processes. Altogether, our investment in GE reflects confidence in a stable, future-focused company that’s positioned at the center of global aerospace and industrial growth.

BSD Analysis:
GE Aerospace enters 2026 as the undisputed "gatekeeper" of the global aviation industry, boasting a record order backlog valued at approximately $190 billion. For the 2026 fiscal year, management has issued a cautious but robust adjusted EPS guidance of $7.10 to $7.40 on projected low-double-digit revenue growth. The company’s "FLIGHT DECK" lean operating model has successfully mitigated supply chain fragility, allowing for a record target of 2,000 LEAP engine deliveries this year in partnership with Safran. Strategic catalysts for 2026 include the certification of the GE9X engine for the Boeing 777X and the ramp-up of the Defense & Propulsion Technologies segment, which saw a 61% surge in orders. Analysts maintain a "Strong Buy" rating with price targets trending toward the $350–$380 range, citing the company’s massive free cash flow generation and aggressive share repurchase program.

Pitch Summary:
Rockwell Automation is another “picks and shovels” investment in the Industrials sector—an established company well-positioned to benefit from reshoring trends, increased defense spending, and the broader adoption of automation and AI in manufacturing. As the economy grows, we expect more industries to invest in faster, smarter, and more reliable production systems, which directly supports demand for Rockwell’s offerings. Its portfolio of automation technologies—including sensors, software, and control systems—helps make domestic manufacturing more efficient and cost-effective. In the defense space, Rockwell also supplies critical systems used in military production facilities. Unlike Boeing, Rockwell is not a turnaround story. It is already a key enabler of advanced manufacturing and a leader in industrial AI, offering solutions for predictive maintenance, quality control, and digital twins that optimize factory operations with leaner workforces. We saw compelling demonstrations of Rockwell’s technology at Nvidia’s GTC conference in March, which reinforced our investment thesis. We began accumulating shares of Rockwell in early March at an average price of approximately $271 per share.

BSD Analysis:
Rockwell Automation enters fiscal 2026 with a sharpened focus on "Factory-of-the-Future" initiatives, recently raising its adjusted EPS guidance to a midpoint of $11.80 following a strong Q1 earnings beat. The company is successfully transitioning from an infrastructure provider to an AI-operationalization leader, with its Intelligent Devices segment growing 16% year-over-year. For 2026, management has reaffirmed an organic sales growth outlook of 2% to 6%, anticipating a gradual sequential improvement in industrial capital spending. The primary strategic catalyst is the expansion of recurring revenue through industrial cybersecurity and OT-managed services, highlighted by a recent multi-plant win with Hindalco Industries. While geopolitical trade uncertainty remains a variable, Rockwell’s completion of a massive $6.2 billion share buyback program reinforces its commitment to high-yield capital returns.

Pitch Summary:
Howmet Aerospace stood out. Beyond its direct connection to Boeing, Howmet is well positioned to benefit from broader sector tailwinds, including rising demand in aerospace and defense and the growing emphasis on building resilient domestic supply chains. As a key supplier of critical components for both commercial and military aircraft, Howmet plays an essential role in supporting next-generation manufacturing. Its expertise in advanced materials and precision engineering makes it a go-to partner for aerospace companies raising quality standards and adopting new technologies. We began building a position in Howmet in early March at an average cost of $130 per share.

BSD Analysis:
Howmet Aerospace enters 2026 as a premier "pick-and-shovel" winner of the aerospace super-cycle, with its shares trading near all-time highs of $225. The company is benefiting from a "once-in-a-generation" demand surge for engine components and fasteners, recently raising its 2026 guidance to reflect double-digit growth in its commercial aerospace segment. For 2026, the investment case is bolstered by an elite 30.1% return on equity and a consistent 25.7% operating margin, highlighting superior execution in a supply-constrained market. A major upcoming catalyst is the Technology and Markets Day on March 10, 2026, where management is expected to unveil a multi-year capacity expansion plan to support record orders from GE Aerospace and Airbus. Analysts maintain a "Moderate Buy" consensus with a median price target of $247.50, viewing the firm as a resilient defensive growth play.

Pitch Summary:
Long-time clients may recall our liquidation of Boeing in early January 2024 following the Alaska Airlines door plug incident. We exited at around $227.62. Following a management shakeup, however, with new leadership under former engineer Kelly Ortberg, we noticed the firm was working to bounce back from safety issues, production problems, and financial losses. The company focus had decisively shifted to quality, stabilizing aircraft output, and rebuilding trust. We viewed Boeing’s commercial side as a turnaround story, accommodated by the steady income provided by the firm’s defense business. WestEnd began accumulating shares in December 2024 at an average price of $175.47. With strong demand for air travel and a huge backlog of plane orders, delivering aircraft on time is crucial, in which Boeing has demonstrated significant improvement this year. While the latest tragic Air India crash slightly hit the stock, it has recovered as it became apparent that pilot error was the most likely cause. We remain confident that Boeing can further improve execution and take advantage of industry trends like reshoring and increased defense spending, while capitalizing on high demand from China after the country lifted its ban Boeing deliveries due to the temporary tariff truce.

BSD Analysis:
Boeing enters 2026 at a historic pivot point, with the market increasingly viewing this as the definitive "turnaround year" following years of production and regulatory setbacks. The company has officially received FAA approval to ramp up 737 MAX production, aiming to reach full capacity by late 2026, while concurrently targeting a production rate of 10 aircraft per month for the 787 Dreamliner. Management has projected low single-digit billions in positive free cash flow for 2026, which would mark the first sustainably positive cash flow year since the pre-MAX crisis era. The certification of the 737 MAX 7 and MAX 10 variants remains the primary product catalyst for the year, alongside a record order backlog that now exceeds $636 billion. While the stock has rallied to a two-year high near $250, high leverage and continued FAA scrutiny remain the primary risks for the fiscal year.

Pitch Summary:
Money Forward is the dominant provider of cloud-based accounting software for small-to-medium-sized businesses in Japan, operating in a duopoly with Freee. Japan is in the very early stages of its transition from on-premises to cloud-based accounting software, with approximately 20% of small businesses having made the shift. Since our initial investment in April 2024, the company has delivered results in line with our thesis, with cloud accounting revenues growing close to +35% year-on-year in 2024 and a similar level expected this year. Despite this, investors focused on near-term margins, culminating in capitulation in January 2025. Following improved disclosure around long-term margin targets, the share price rebounded sharply.

BSD Analysis:
Money Forward is Japan’s leading personal and SMB financial management platform, riding the slow but powerful digitization of accounting and finance workflows. Its SaaS products are deeply embedded in daily operations, creating strong switching costs. Growth is driven by cloud adoption among SMEs and regulatory-driven digital compliance. Margins are still maturing as the company prioritizes growth and ecosystem buildout. Over time, operating leverage should be meaningful as customer cohorts age. Japan’s conservative software market actually extends the runway. Money Forward is a long-term compounder in an underpenetrated SaaS market.

Pitch Summary:
Rightmove is the dominant real estate advertising portal in the UK, with ~85% share of time spent on property portals by UK consumers. We first discussed our investment in Rightmove in November 2023, when the stock was trading at approximately 18x forward earnings, its lowest multiple in a decade, following US-listed CoStar Group’s offer to acquire OnTheMarket. Fast-forward to today, and OnTheMarket still only attracts a 5% share of consumer time spent on property portals, while Rightmove remains dominant, with more than 80% share of time spent on property portals and more than 95% brand awareness among home movers. In this time, Rightmove has grown revenues by +10% in 2023, +7% in 2024, and is set to grow by a further +9% by the end of this year, driven by subscription upgrades and price increases.

BSD Analysis:
Rightmove is the UK’s most dominant online property portal, commanding overwhelming traffic share and pricing power over estate agents. Even in weak housing markets, agents can’t afford to leave the platform, giving Rightmove remarkable revenue resilience. The business converts market leadership into best-in-class margins and cash flow. ARPA growth remains the primary lever, and Rightmove has consistently pushed pricing without meaningful churn. New products and data services add incremental monetization without altering the core model. Housing cycles affect sentiment more than fundamentals. This is one of the cleanest marketplace monopolies in Europe.

Pitch Summary:
The author argues that Maravai LifeSciences ($MRVI) is being mispriced despite near-term negativity around management’s outlook. They emphasize Maravai’s substantial mRNA manufacturing footprint (~230k+ sqft across R&D to GMP), much of which was partially government-funded, implying a replacement cost far above the current equity value. Using conservative assumptions, the author estimates ~$460m in replacement value for facilities alone, with the Biologics Safety Testing (BST) segment worth ~$1bn based on precedent transactions and ~$450–500m for TriLink. This implies ~$5.50/share in asset value, versus prior rumored strategic bids in the $8–9/share range. The pitch highlights strategic scarcity value, particularly for U.S.-based mRNA capacity, with potential acquirers lacking domestic capabilities.

BSD Analysis:
The CDMO and life sciences tools industry is structurally tightening as governments and biopharma prioritize supply-chain resilience, reshoring, and mRNA readiness beyond COVID. Maravai’s competitive position lies in its specialized mRNA and nucleic-acid manufacturing assets, which are capital-intensive, slow to replicate, and increasingly strategic. While near-term earnings are pressured by post-pandemic normalization and potential management “kitchen sinking,” asset value and strategic optionality remain largely intact. Precedent M&A activity—such as Waters Corporation acquiring Becton Dickinson assets—supports high multiples for quality life sciences infrastructure. Potential buyers like Thermo Fisher Scientific or Agilent Technologies would gain scarce domestic mRNA capacity overnight, accelerating strategic positioning. The key risk is timing: M&A windows can remain shut longer than expected if biopharma spending stays muted. However, partnerships with Lonza and Danaher validate asset quality. If strategic demand for domestic mRNA capacity resurfaces, MRVI’s downside appears asset-backed while upside is driven by takeout optionality rather than near-term earnings.

Actual Post Content:
$mrvi baggy posting before he gets smoked (again) on new mgmt kitchen sinking outlook. But CDMO commentary favors reshoring. Mrvi has 230k+ sqft of mRNA manufacturing capacity from research to gmp grade. Mrvi received $39m from govt for 50% of construction cost for 32k sqft. Flanders 2 facility ~ $2.4k per sqft. Assume $2k per sqft for whole thing. Thats $460M replacement cost. BST segment does ~$50m of ebitda was growing dd’s precovid. $wat buying bdx assets at 18x shows what strategic will pay. So call BST worth $1B, trilink worth $450-$500m. you’re at $5.50/shr. We kno strategics want the asset and last rumored bids were in the $8-9/shr range. TMO has no domestic mRNA manufacturing capacity. Agilent is v much in play. Mrvi has partnership with Lonza and DHR. If RFK going to focus on cane sugar, then M&A window should open. MRVI has a for sale sign up. Hard to imagine they don’t get taken out.

URL: https://x.com/cousingraig/status/1948386894204555432

Pitch Summary:
The author argues that Mercer International ($MERC) is a deeply undervalued commodity manufacturing business trading at less than half of replacement cost, creating an attractive asymmetric setup. After monitoring the company for an extended period, the author has initiated a new position, citing improving timing and depressed sentiment. A key validation point is significant insider buying by the largest shareholder, Peter R. Kellogg, who recently increased his stake to over 25% following a ~$2.5m purchase. The author views this as strong confirmation that intrinsic value materially exceeds the current share price. Given the asset base and cyclicality of the business, the stock is framed as having potential to double over the coming months if conditions normalize.

BSD Analysis:
The global pulp and paper industry is structurally cyclical, with returns driven by capacity discipline, input costs, and commodity price inflections rather than secular growth. Mercer’s competitive position is anchored in hard assets with long lives and high replacement costs, which provides downside protection when trading materially below asset value. Insider accumulation at scale is particularly relevant in capital-intensive industries, where informed owners best understand mid-cycle earnings power and replacement economics. The primary risk is timing: commodity downturns can persist longer than expected, pressuring cash flows and balance-sheet flexibility. However, replacement cost asymmetry limits long-term downside absent structural impairment of demand. Valuation reflects trough-like conditions, assigning little credit to normalized margins or operating leverage. If pulp pricing stabilizes or recovers modestly, earnings power could snap back disproportionately. In that scenario, multiple expansion toward mid-cycle asset-based valuation could drive substantial equity upside.

Actual Post Content:
New position in $MERC. I have followed this business over time, and been waiting for the right moment to get big. I built a toe-hold position over the last few days. It looks like the largest owner agrees the stock is cheap, as he backed up the truck recently and now owns over 25% of the company. I love buying beaten down commodity manufacturing businesses at less than half of replacement cost. Stock could easily double from these levels over the next few months. Mercer International Insider Bought Shares Worth $2,470,000, According to a Recent SEC Filing (MT Newswires) Peter R Kellogg, 10% Owner, on July 22, 2025, executed a purchase for 760,000 shares in Mercer International (MERC) for $2,470,000. Following the Form 4 filing with the SEC, Kellogg has control over a total of 23,455,000 common shares of the company, with 610,000 shares held directly and 22,845,000 controlled indirectly.

URL: https://x.com/multimismanaged/status/1948381629052838039

Pitch Summary:
The author argues that InMode ($INMD) represents a compelling short despite appearing optically cheap on historical metrics. While the stock screens at ~3× earnings ex-cash and has been aggressively buying back shares, the author believes this masks a rapidly deteriorating core business. Revenue is declining quickly as competition intensifies and market share erodes. When annualizing the most recent quarter, earnings power implies a valuation closer to ~10× ex-cash, which is no longer compelling for a shrinking business. Most concerning, consumables and service revenue are falling, signaling declining utilization of the installed base rather than just weaker new sales. The setup is framed as a value trap with downside that is relatively uncorrelated to broader market moves.

BSD Analysis:
The aesthetic medical device industry has shifted from a high-growth innovation cycle to a more competitive, fragmented market where differentiation is narrowing. InMode’s competitive position has weakened as lower-cost and faster-iterating competitors compress pricing and reduce switching costs for practitioners. Declining consumables revenue is a critical negative signal, as it undermines the recurring revenue thesis and suggests structural demand softness rather than cyclical pause. Capital returns via buybacks cannot offset falling utilization, as financial engineering does not restore lost relevance or pricing power. Secular demand for aesthetics persists, but value accrues to platforms with continuous clinical innovation and ecosystem lock-in. Valuation appears deceptively low because consensus earnings underestimate the speed of normalization downward. The key risk to the short is a stabilization in procedure volumes or successful product refresh, though evidence remains limited. Absent a demand inflection, INMD’s earnings base likely continues to reset lower, justifying sustained underperformance.

Actual Post Content:
Here's a unique short. I think that $INMD is a great short here. A lot of value guys look at it with good historical growth, trading at 3x earnings ex cash and buying back shares aggressively. Unfortunately, even if the buyback continues I think this is a value trap. Revenue is dropping fast as competition is eating their market share quickly. Annualising their last quarter gets them to 10x earnings ex cash, which isn't that cheap for a declining business. The most concerning is that consumables and service revenue is dropping, suggesting that utilisation of existing machines is dropping. This feels like a unique, uncorrelated short that will underperform the market going forward.

URL: https://x.com/finphysnerd/status/1948376919453614377

Pitch Summary:
MongoDB ($MDB) is positioned as a core layer of enterprise AI infrastructure, serving as the system of record for AI-native applications. The author highlights Atlas, MongoDB’s cloud platform, which is growing at 20%+ and now accounts for the majority of revenue, as the primary vehicle for AI-driven monetization. With relatively few customers currently spending over $1m annually, the pitch sees significant upside as AI workloads scale, persist, and become mission-critical. MongoDB’s integrated vector search, retrieval capabilities, and developer-first tooling are viewed as strategically important for real-time and agentic AI use cases. The argument is that the market continues to value MongoDB as a traditional database vendor rather than a foundational AI infrastructure provider.

BSD Analysis:
The enterprise data infrastructure market is consolidating around platforms that combine transactional integrity with real-time retrieval and analytics, creating high switching costs once embedded. MongoDB’s competitive position is strengthened by its flexible document model, cloud-native architecture, and tight integration across data storage, search, and AI tooling. Secular AI adoption expands its addressable market beyond application databases into inference-time data access and retrieval-augmented generation. The key risk is intensifying competition from hyperscalers bundling databases and vector services into broader stacks, potentially pressuring pricing and differentiation. However, MongoDB’s developer mindshare and workload portability across clouds support durable adoption. Valuation reflects skepticism around near-term consumption normalization rather than long-term AI-driven expansion. If Atlas continues to scale and AI workloads mature into steady-state production spend, MongoDB’s earnings power and multiple could re-rate meaningfully as an AI infrastructure compounder.

Actual Post Content:
$MDB $NVO $MDB the examples of MongoDB generative AI successes go on and on! This is just the beginning! $MDB Numbers in plain sight: Q1 FY26 revenue came in at $549 million, up 22 percent YoY, and management now pegs full-year sales around $2.3 billion. Atlas, the cloud engine that rolls new AI features to every customer in real time, drove $394 million this quarter, climbing 26 percent and accounting for 72 percent of total revenue. MongoDB now counts 57,100 paying organizations, each “logo” is one distinct company on the customer slide, yet only 320 of them spend more than $1 million a year. Put differently, almost every enterprise already on the platform still has room to turn up usage as AI workloads move from one-off model training to nonstop, data-hungry applications. Fresh launches like the Voyage 3.5 retrieval models and the Model Context Protocol tighten MongoDB’s grip on that real-time AI stack, and the resulting cash is compounding fast. https://investors.mongodb.com/news-releases/news-release-details/mongodb-inc-announces-first-quarter-fiscal-2026-financial $MDB Rough valuation assumptions MongoDB just posted $2.01 billion in revenue for fiscal 2025, with their Atlas cloud platform driving $1.43 billion of that (71% of total). The company is growing Atlas at 24% annually and has built an impressive customer base of 57,000 accounts, including 320 that spend over $1 million per year. With 120% net retention, every customer cohort naturally expands by 20% annually without adding new logos. The AI infrastructure market is exploding; multiple research firms project it will grow from $35 billion today to $223-394 billion by 2030. Here's the simple math: if just a few thousand large enterprises globally decide they need robust AI data infrastructure and are willing to spend $1+ million annually on it, that creates a massive new revenue pool. MongoDB's database with built-in vector search is perfectly positioned to capture this wave, especially since 70% of the Fortune 100 already uses Atlas. The straightforward path to a much bigger MongoDB: -Current Atlas revenue: $1.43B growing at 24% annually -Conservative growth: Even if Atlas only" grows 15-18% annually, that's $3+ billion by 2030 -AI customer premium: Add 1,000-2,000 new enterprise customers spending $1-2M each on AI workloads -That's $4-6 billion in total revenue just from these two drivers Plus existing customer expansion and international growth At $4-6 billion in revenue, where it becomes one of the TOP players for the data and memory layer of the AI revolution, and trades like the exciting AI company it really (Let's not even compare with $PLTR), MongoDB would trade at very different multiples. Here's what we've actually seen from comparable companies with an AI infrastructure edge: Current AI Infrastructure Multiples (2024-2025): -Snowflake: 19-25x revenue (data platform/AI infrastructure) -Datadog: 14-16x revenue (observability/monitoring) -CrowdStrike: 13-16x revenue (cybersecurity platform) -AI Infrastructure category average: 47.7x revenue (though this includes early-stage companies) Realistic MongoDB Scenarios: -Conservative (12x): $5B revenue × 12x = $60B valuation (215% upside) -Optimistic (18x): $5B revenue × 18x = $90B valuation (374% upside) -Current market cap: ~$19B The key is whether MongoDB gets valued as a traditional database (8-12x) or as essential AI infrastructure (15-20x) or even higher into pure AI hype which is entirely possible with massive adoption. Infrastructure companies consistently lead with the highest multiples in the AI space, so if MongoDB successfully positions itself there, the higher multiples become realistic. The investment thesis is simple: if MongoDB successfully positions itself as essential AI data layer and memory play, rather than just another database (because they are not JUST a database but an AI company!), and if they can land a meaningful number of high-value AI customers, the revenue and valuation re-rating opportunity is VERY substantial. The AI boom creates a once-in-a-decade chance for AI picks and shovels companies, in this case, an essential one to dramatically expand their addressable markets, and MongoDB is uniquely positioned to benefit! The market caps with huge growth and flywheel AI / data / memory integration could be MUCH higher."

URL: https://x.com/JKeynesAlpha/status/1948542963753033729

Pitch Summary:
Howmet Aerospace was also a top contributor to relative performance. The specialized aircraft components manufacturer’s Q1 2025 earnings exceeded expectations, as the business continued to benefit from cyclical aerospace recovery and aftermarket demand. Howmet has gained market share by investing through the down cycle while competitors pulled back. The company also benefits from industrial gas turbine demand supporting power generation needs for AI infrastructure.

BSD Analysis:
Howmet is a pure-play on the higher-value parts of aerospace and defense—engine components, fasteners, and structural pieces that need to perform flawlessly under stress. It benefits from both commercial build-rate recovery and durable defense demand. Once qualified on a program, its parts tend to stay there for the life of the platform, which can be measured in decades. The mix is tilted toward content on newer, more fuel-efficient aircraft, which should have longer and richer production runs. Margins are expanding as volumes recover and the company leans into operational efficiency. This is not a household brand, but it sits right where the money is in the aerospace supply chain. You own it to monetize long-lived platforms, not short-term cycle noise.

Pitch Summary:
Broadcom, another top contributor in AI infrastructure, has benefited from hyperscalers’ interest in a second source behind NVIDIA’s merchant silicon. The semiconductor company leads in custom silicon development, offering lower cost and better efficiency for specific workloads that don't require maximum performance GPUs. The market also continues to evolve as custom silicon has gained share relative to merchant chips. Broadcom's leadership position makes it a clear beneficiary of this shift.

BSD Analysis:
Broadcom is an unapologetic cash machine sitting at the intersection of AI hardware, networking, and infrastructure software. Its custom chips and high-speed networking components are embedded in the AI build-out, while VMware adds an enormous recurring software base tied to enterprise data centers. The acquisition playbook is ruthless but proven: slash non-critical spend, focus on key customers, and milk the asset for cash. That makes some users unhappy, but shareholders rarely complain about the margin profile. Regulatory and customer concentration risks are table stakes at this scale, yet switching away from Broadcom is easier said than done. The company is less a “semi cyclical” and more an oligopolistic infrastructure provider. At the right price, it’s one of the more compelling cash-flow compounding stories in tech.

Pitch Summary:
Oracle was a top contributor to relative performance. The company posted strong results with significant growth in remaining performance obligations, which the market viewed favorably as an indicator of future revenue growth. The enterprise software company has successfully established itself as a major cloud provider by procuring GPU availability ahead of other hyperscalers and making architectural decisions that allow smaller, compartmentalized clouds versus competitors’ mega-clouds. This technology advantage has helped Oracle win sovereign deals globally and positions the company well as AI deployment continues.

BSD Analysis:
Oracle has gone from punchline to serious cloud contender far faster than the market narrative suggests. Its Gen2 cloud is gaining share in data-heavy and AI workloads where performance and existing database relationships matter more than being the cool kid. The legacy database and support business is still a cash geyser, funding aggressive capex and shareholder returns. The Cerner acquisition was rough out of the gate but gave Oracle a powerful foothold in healthcare data and workflows. Customers grumble about licensing and audits, but those same dynamics keep revenue sticky and margins thick. Oracle isn’t trying to be everything to everyone; it’s targeting specific, lucrative workloads where its stack has a real edge. This is a slow-burn transition story where patience is rewarded.

Pitch Summary:
E Ink Holdings, a Taiwanese manufacturer of e-paper film that operates a near-monopoly, also suffered during the quarter from tariff-related sentiment. The Americas are an increasingly relevant part of its business following a large deal with Wal-Mart. The company also signaled that there may be reduced demand for its consumer electronics products in the second half of the year. However, we believe the real value of the business lies in its electronic signage labels (ESLs), and as the adoption of this novel technology spreads throughout the world, the company will have a bright future ahead.

BSD Analysis:
E Ink is a monopolistic, essential pure-play on sustainable digital signage whose stock is poised for a multi-year earnings surge. The core thesis is driven by a powerful, non-cyclical structural tailwind: the replacement of traditional LCD and paper displays with ultra-low-power electronic shelf labels (ESLs) and digital signage. This shift is fueled by the environmental benefits and labor savings required by major global retailers. The company is aggressively expanding capacity: it plans to build new production lines, totaling NT$3.37 billion, to meet the rapidly growing demand. This demand is already translating to superior financials: Gross Margin rose to 56.44% and revenue is expected to hit historical highs through 2028. E Ink is an indispensable supplier to the digital transformation of retail and advertising.

Pitch Summary:
Like all major Chinese consumer technology platforms, PDD Holdings suffered from more negative investor sentiment relating to the uptick in domestic competitive intensity. Its international e-commerce platform, Temu, was also hit by import tariffs in the U.S. While these impacts on its business are currently negative, PDD remains the lowest-cost, most advantaged e-commerce platform in the largest e-commerce market in the world. There is still substantial scope for Temu to grow outside of the U.S. Should the company decide to start returning capital to shareholders, the prospects for an attractive return are considerable. Meanwhile, the company trades at what we view to be an extremely favorable multiple.

BSD Analysis:
PDD Holdings, the engine behind Pinduoduo and Temu, is a high-leverage, high-growth e-commerce disruptor executing a margin-eroding land grab to dominate global markets. The core thesis is a structural, aggressive pivot to supply chain and agriculture: the company's mission is to digitize agriculture, connecting farmers directly with a massive consumer base. The velocity is undeniable: Temu's global Gross Merchandise Value (GMV) hit an estimated $35 billion in just the first half of 2025. Management is deliberately trading near-term profitability for market share, evidenced by the RMB 100 billion support program for farmers and merchants. This strategy, however, caused operating margins to fall to 25% in Q3 2025. The stock is a conviction bet on its technological differentiation and long-term vision to dominate the intersection of technology and agriculture.

Pitch Summary:
Wizz Air, an Eastern European ultra-low-cost airline, released weak results from a profitability standpoint and signaled to the market that costs would likely remain elevated during its fiscal year 2026. The company is dealing with aircraft groundings due to a mechanical problem that has left it without about 20% of its fleet. This is a problem in an industry with such sizeable operating leverage (and deleverage). However, looking past F26 into FY27, when we believe these headwinds should start to abate, this structurally advantaged business is attractively valued.

BSD Analysis:
Wizz Air is the aggressively positioned, high-growth low-cost airline whose premium valuation is justified by its superior cost structure and ambitious expansion. The core thesis is driven by its cost leadership strategy, positioning it as the third-largest low-cost airline in Europe. The company is relentlessly expanding its market share and capacity, particularly across Central and Eastern Europe, which offers higher growth potential. Wizz Air maintains a strong liquidity position and a strategic approach to managing capacity, which is essential for maximizing operational efficiencies. The positive outlook is supported by its ability to manage capacity, optimizing seat availability and route efficiency, which strengthens its competitive advantage. The stock is a conviction bet on the long-term, structural growth of cost-conscious European air travel.